SymBio Pharmaceuticals

2021.08.04: Analyst Report[Update report] (Shared Research)
2021.08.04: Notice Concerning Non-operating Expenses
2021.08.04: Summary of Financial Statements for the First Six Months of Fiscal Year Ending December 31, 2021 [Japanese GAAP] (Non-consolidated)
2021.08.02: Collaborative research with Kyoto University on mechanism of response of bendamustine for diffuse large B-cell lymphoma
2021.07.15: Notice of Appointment of Corporate Officer
2021.07.15: Collaborative research with Gunma University to explore new indications for bendamustine and rigosertib
2021.06.29: Onconova Therapeutics announces an update on the Phase 1/2a Trial of Rigosertib-Nivolumab Combination in KRAS+ Non-Small Cell Lung Cancer
2021.06.23: Notice of Changes of Director
2021.06.18: Onconova Therapeutics announces the synergistic anti-cancer activity of rigosertib combined with immune checkpoint blockade
2021.06.16: Analyst Report[Full report] (Shared Research)
2021.06.07: Chimerix receives U.S. Food and Drug Administration approval for brincidofovir for the treatment of smallpox
2021.06.01: Analyst Report[Basic Report] (Fair Research)
2021.05.25: New Patent Issued in Japan for Antiviral Agent Brincidofovir
2021.05.21: Analyst Report[COMPANY RESEARCH AND ANALYSIS REPORT] (FISCO)
2021.05.19: Chugai receives NHI price listing for polatuzumab vedotin for treatment of relapsed or refractory diffuse large B-cell lymphoma
2021.05.13: Analyst Report[Update report] (Shared Research)
2021.05.13: Notice of Appointment of Corporate Officer
2021.05.13: Summary of Financial Statements for the First Quarter of Fiscal Year Ending December 31, 2021 [Japanese GAAP] (Non-consolidated)
2021.05.10: SymBio submits a partial change application for use of TREAKISYM Liquid Formulation for Rapid Infusion (RI) administration
2021.04.28: SymBio receives approval for use of TREAKISYM Ready-To-Dilute (RTD) Formulation in combination with rituximab and polatuzumab vedotin for treatment of relapsed or refractory diffuse large B-cell lymphoma
2021.04.28: SymBio receives approval for use of TREAKISYM Ready-To-Dilute (RTD) Formulation in combination with rituximab for treatment of relapsed or refractory diffuse large B-cell lymphoma
2021.04.26: U.S. Food and Drug Administration granted fast track designation to antiviral agent brincidofovir IV for the treatment of adenovirus infection in pediatric patients
2021.04.26: Onconova Therapeutics announces first patient dosed in an investigator-initiated Phase 2 study of rigosertib in recessive dystrophic epidermolysis bullosa-associated squamous cell carcinoma
2021.04.23: Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Employees
2021.04.23: Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Directors
2021.03.29: SymBio submits partial change application to extend the shelf life of TREAKISYM Ready-To-Dilute (RTD) Formulation
2021.03.25: Notice of Shareholder Voting Results for the16th Ordinary General Meeting of Shareholders
2021.03.25: SymBio submits a partial change application for use of TREAKISYM Ready-To-Dilute (RTD) Formulation in combination with rituximab for treatment of relapsed or refractory diffuse large B-cell lymphoma
2021.03.25: SymBio submits a partial change application for use of TREAKISYM Ready-To-Dilute (RTD) Formulation in combination with rituximab and polatuzumab vedotin for treatment of relapsed or refractory diffuse large B-cell lymphoma
2021.03.24: Notice of Appointments to the Board of Directors and the Audit & Supervisory Board, and Appointments of Corporate Officers
2021.03.24: Notice Concerning the Issuance of Stock Acquisition Rights to Directors
2021.03.24: Notice Concerning the Issuance of Stock Acquisition Rights to Employees
2021.03.23: SymBio receives approval for use of TREAKISYM in combination with rituximab and polatuzumab vedotin as treatment for relapsed or refractory diffuse large B-cell lymphoma
2021.03.23: SymBio receives approval for use of TREAKISYM in combination with rituximab as treatment for relapsed or refractory diffuse large B-cell lymphoma
2021.03.11: SymBio submits IND Application for Phase 2 Clinical Trial of Anti-viral Drug Brincidofovir IV for treatment of Pediatric Adenovirus Infection
2021.03.03: Information on Shareholders' Meeting: Updated the Page
2021.02.26: Chimerix Announces FDA Extends PDUFA Date of New Drug Application for Brincidofovir as a Medical Countermeasure for Smallpox to July 7, 2021
2021.02.25: Notice concerning Nominations for the Board of Directors / the Audit & Supervisory Board / and Substitute Member for the Audit & Supervisory Board
2021.02.22: Results of Phase III Trial of TREAKISYM in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
2021.02.04: Analyst Report[Update report] (Shared Research)
2021.02.04: 3 Year Mid-Range Plan: FY 2021 to FY 2023
2021.02.04: Notice Concerning Non-Operating Income
2021.02.04: Summary of Financial Statements for the Fiscal Year Ended December 31, 2020 [Japanese GAAP] (Non-consolidated)
2021.01.28: Collaborative research with the Institute of Medical Science, the University of Tokyo, to explore new indications for bendamustine and rigosertib
2021.01.12: Market Launch of TREAKISYM Ready-To-Dilute (RTD) Formulation
2020.12.23: Notice of Appointment of Corporate Officer
2020.12.22: Notice of Conclusion of Syndicated Loan Agreement
2020.12.22: Analyst Report[Full report] (Shared Research)
2020.12.18: Completion, Monthly Exercise Status and Large Volume Exercise of the 51th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2020.12.10: Commencement of in-house sales of the anti-cancer agent Treakisym
2020.12.08: Chimerix Announces FDA Acceptance of New Drug Application for Brincidofovir as a Medical Countermeasure for Smallpox
2020.12.03: Notice of the Large Volume Exercise of the 51st Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2020.12.01: Monthly Exercise Status of the 51st Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2020.11.26: Notice of the Large Volume Exercise of the 51st Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2020.11.24: National Health Insurance (NHI) Price Listing and Market Launch of TREAKISYM Ready-To-Dilute (RTD) Formulation
2020.11.11: Notice of the Large Volume Exercise of the 51st Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2020.11.10: Analyst Report[Update report] (Shared Research)
2020.11.10: Summary of Financial Statements for the First Nine Months of Fiscal Year Ending December 31, 2020 [Japanese GAAP] (Non-consolidated)
2020.11.10: Notice Concerning Non-operating Expenses
2020.11.06: Chimerix Completed Rolling Submission of New Drug Application to FDA for Brincidofovir as a Medical Countermeasure for Smallpox
2020.11.04: Analyst Report[Follow-up Report] (Fair Research)
2020.11.02: Monthly Exercise Status of the 51st Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2020.10.13: Exercise of the 51st Stock Acquisition Rights and Revision to the Specific Uses and Amounts of Funds Raised through the 50th and 51st Stock Acquisition Rights
2020.09.23: SymBio Receives Approval of TREAKISYM Ready-To-Dilute (RTD) Formulation
2020.09.17: Analyst Report[Update report] (Shared Research)
2020.09.17: Revision to Earnings Forecasts for FY 2020 and Mid-Range Plan (FY 2020 to FY 2022)
2020.09.10: Analyst Report[Commercial outlook] (EDISON)
2020.09.09: Last Patient Last Visit (“LPLV”) Achieved in Clinical Study for TREAKISYM Rapid Infusion Liquid Formulation
2020.09.07: Preparation for Sales & Marketing by SymBio's Own Sales Organization